Edgewise Therapeutics Announces Positive Top-Line Data from 12-Week Phase 2 CIRRUS-HCM Trial with EDG-7500 in Obstructive and Nonobstructive Hypertrophic Cardiomyopathy (HCM)
Go back to Edgewise Therapeutics Announces Positive Top-Line Data from 12-Week Phase 2 CIRRUS-HCM Trial with EDG-7500 in Obstructive and Nonobstructive Hypertrophic Cardiomyopathy (HCM)| (NASDAQ: EWTX) | Delayed: 45.32 -1.62 (3.45%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $46.94 | 52 Week High | $ | |||
| Open | $46.79 | 52 Week Low | $ | |||
| Day High | $46.93 | P/E | N/A | |||
| Day Low | $45.32 | EPS | $ | |||
| Volume | 1,991,954 | |||||
